Finance entity
Coverage clusters in markets, which accounts for 2 of those 3, with the remainder spread across 1 other category. Alphabet is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 150-day window averages about 0.1 stories each week.
Last mentioned: 2h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Coverage clusters in markets, which accounts for 2 of those 3, with the remainder spread across 1 other category. Alphabet is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 150-day window averages about 0.1 stories each week. They are less corroborated than the beat average, carrying 2.7 original sources each against 2.9 for the same window. The 7 average consequence score is above the beat benchmark of 6.1 in the same window. Merck appears in 3 tracked Finance stories published from March 24, 2026 through August 20, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 1603 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Merck. Shared-story counts are live from our verified record — not editorial picks.
Sentiment Review
Major analysts maintain existing price targets and ratings despite the earnings beat.
Analyst Upgrade
Wall Street Zen upgrades CDXS rating following financial results.
Q4 2025 Earnings
Codexis reports surprise profit and revenue beat.
TD Cowen Conference
CEO touts ECO Synthesis push and 2026 inflection targets.
For finance readers, Aug. 19 was a case study in cross-asset relief: Treasury buyback news pulled the 30-year yield off its highest since 2007, feeding a 0.21% S&P 500 gain, while a more than 137% Moderna surge drove healthcare to a record 2.9% gain. The support for risk appetite masks a hawkish Fed minutes message and an unresolved long-term rate threat to AI-heavy valuations.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Codexis reported a significant Q4 2025 earnings beat, driven by its ECO Synthesis platform and expanding CDMO partnerships. Despite a raised 2026 revenue outlook and a surprise GAAP profit, analyst sentiment remains largely unchanged as the market awaits further commercial validation of its RNA manufacturing technology.
Merck is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
